FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia
Status:
Recruiting
Trial end date:
2025-12-15
Target enrollment:
Participant gender:
Summary
This Phase I open-label dose escalation study is conducted in two stages with a primary
endpoint to identify the maximum tolerated dose (MTD) of FT538 when administered with
daratumumab in patients 12 years and older with advanced acute myeloid leukemia (AML) and
related myeloid diseases.